PMC:7195088 / 24803-25323 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T121","span":{"begin":106,"end":114},"obj":"Disease"},{"id":"T122","span":{"begin":393,"end":401},"obj":"Disease"},{"id":"T123","span":{"begin":471,"end":479},"obj":"Disease"}],"attributes":[{"id":"A121","pred":"mondo_id","subj":"T121","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A122","pred":"mondo_id","subj":"T122","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A123","pred":"mondo_id","subj":"T123","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"Comparison of oseltamivir plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with mild COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19. Open-label RCT (NCT04303299, not yet recruiting). Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T124","span":{"begin":408,"end":413},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"}],"text":"Comparison of oseltamivir plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with mild COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19. Open-label RCT (NCT04303299, not yet recruiting). Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T317","span":{"begin":14,"end":25},"obj":"Chemical"},{"id":"T318","span":{"begin":31,"end":42},"obj":"Chemical"},{"id":"T319","span":{"begin":47,"end":58},"obj":"Chemical"},{"id":"T320","span":{"begin":64,"end":83},"obj":"Chemical"},{"id":"T321","span":{"begin":64,"end":73},"obj":"Chemical"},{"id":"T322","span":{"begin":74,"end":83},"obj":"Chemical"},{"id":"T323","span":{"begin":122,"end":141},"obj":"Chemical"},{"id":"T324","span":{"begin":122,"end":131},"obj":"Chemical"},{"id":"T325","span":{"begin":132,"end":141},"obj":"Chemical"},{"id":"T326","span":{"begin":147,"end":158},"obj":"Chemical"},{"id":"T327","span":{"begin":163,"end":172},"obj":"Chemical"},{"id":"T328","span":{"begin":173,"end":182},"obj":"Chemical"},{"id":"T329","span":{"begin":188,"end":199},"obj":"Chemical"},{"id":"T330","span":{"begin":204,"end":215},"obj":"Chemical"},{"id":"T331","span":{"begin":221,"end":240},"obj":"Chemical"},{"id":"T332","span":{"begin":221,"end":230},"obj":"Chemical"},{"id":"T333","span":{"begin":231,"end":240},"obj":"Chemical"},{"id":"T334","span":{"begin":245,"end":254},"obj":"Chemical"},{"id":"T335","span":{"begin":255,"end":264},"obj":"Chemical"},{"id":"T336","span":{"begin":270,"end":281},"obj":"Chemical"},{"id":"T337","span":{"begin":287,"end":298},"obj":"Chemical"},{"id":"T338","span":{"begin":303,"end":312},"obj":"Chemical"},{"id":"T339","span":{"begin":313,"end":322},"obj":"Chemical"},{"id":"T340","span":{"begin":328,"end":339},"obj":"Chemical"},{"id":"T341","span":{"begin":345,"end":356},"obj":"Chemical"},{"id":"T342","span":{"begin":408,"end":413},"obj":"Chemical"}],"attributes":[{"id":"A317","pred":"chebi_id","subj":"T317","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A318","pred":"chebi_id","subj":"T318","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A319","pred":"chebi_id","subj":"T319","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A320","pred":"chebi_id","subj":"T320","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A321","pred":"chebi_id","subj":"T321","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A322","pred":"chebi_id","subj":"T322","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A323","pred":"chebi_id","subj":"T323","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A324","pred":"chebi_id","subj":"T324","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A325","pred":"chebi_id","subj":"T325","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A326","pred":"chebi_id","subj":"T326","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A327","pred":"chebi_id","subj":"T327","obj":"http://purl.obolibrary.org/obo/CHEBI_367163"},{"id":"A328","pred":"chebi_id","subj":"T328","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A329","pred":"chebi_id","subj":"T329","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A330","pred":"chebi_id","subj":"T330","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A331","pred":"chebi_id","subj":"T331","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A332","pred":"chebi_id","subj":"T332","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A333","pred":"chebi_id","subj":"T333","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A334","pred":"chebi_id","subj":"T334","obj":"http://purl.obolibrary.org/obo/CHEBI_367163"},{"id":"A335","pred":"chebi_id","subj":"T335","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A336","pred":"chebi_id","subj":"T336","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A337","pred":"chebi_id","subj":"T337","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A338","pred":"chebi_id","subj":"T338","obj":"http://purl.obolibrary.org/obo/CHEBI_367163"},{"id":"A339","pred":"chebi_id","subj":"T339","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A340","pred":"chebi_id","subj":"T340","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A341","pred":"chebi_id","subj":"T341","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A342","pred":"chebi_id","subj":"T342","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"}],"text":"Comparison of oseltamivir plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with mild COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19. Open-label RCT (NCT04303299, not yet recruiting). Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T187","span":{"begin":403,"end":452},"obj":"Sentence"},{"id":"T188","span":{"begin":453,"end":520},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Comparison of oseltamivir plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with mild COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19. Open-label RCT (NCT04303299, not yet recruiting). Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks)."}